Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study

Overview of attention for article published in EJNMMI Research, September 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 15 publications that cite this research output.

15

The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.

Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Article in European Journal of Nuclear Medicine and Molecular Imaging (May 2024)

Women's Health Update: Growing Role of PET for Patients with Breast Cancer

Article in Seminars in Nuclear Medicine (February 2024)

Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer

Article in Medicina (February 2024)